Blog
Where Will Rocket Lab Stock Be in 10 Years?
The space economy is growing at an unheard-of pace. Soon, SpaceX may even have artificial intelligence (AI) data centers in orbit, powered by its gigantic Starship system. However, you cannot invest
Prediction: 3 Stocks That'll Be Worth More Than Walmart 5 Years From Now
Walmart (NASDAQ: WMT) surpassed $1 trillion in market capitalization earlier this year, becoming the 10th U.S. company in the exclusive club.
Despite being smaller companies than Walmart today (as
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Novartis (NYSE: NVS) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are extensive, spanning oncology, immunology, neuroscience, respiratory care
JFrog's CTO Sold Shares Worth $2.5 Million. Is the Stock a Buy or Sell?
JFrog (NASDAQ:FROG), a leader in DevOps software solutions, reported a sale by its co-founder and Chief Technology Officer Yoav Landman on Feb. 12 and Feb. 13, 2026. Mr. Landman reported the sale of
Is CrowdStrike Stock a Buy After Falling 17% Year to Date?
Shares of cybersecurity specialist CrowdStrike (NASDAQ: CRWD) are down meaningfully early in 2026, despite the company announcing another quarter of strong growth and cash generation when it
Betting Against Wall Street: The Inverse ETF Surge No One Is Talking About
It's been nearly two decades since the Global Financial Crisis sparked a wave of bank failures, casting a dark cloud over the financial services sector. Fortunately, things are different today.
2 Quantum Computing Stocks That Could Make a Millionaire
Quantum computing is still early, messy, and wildly speculative, which is exactly why the upside for patient, risk‑tolerant investors is so intriguing.
If this technology can cross the chasm from
Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million
On February 17, 2026, Perceptive Advisors disclosed a significant buy of 431,432 shares of Praxis Precision Medicines (NASDAQ:PRAX), with an estimated transaction value of $80.34 million based on
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position
On February 17, 2026, Perceptive Advisors reported a buy of Celcuity (NASDAQ:CELC), adding 203,881 shares in the fourth quarter, with an estimated transaction value of $16.76 million based on
2 Financial Stocks Poised for a Comeback in 2026
Two of the most consistent, reliable, and best financial stocks over the past decades -- Visa (NYSE: V) and Moody's (NYSE: MCO) -- have struggled in recent months.
Visa, the leading payment
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction
On February 17, 2026, Perceptive Advisors disclosed a buy of 978,662 shares of Apogee Therapeutics (NASDAQ:APGE), with an estimated transaction value of $61.64 million based on quarterly average
My 5 Favorite Dividend Stocks to Buy Right Now
Does your portfolio need some new income investments? Maybe you're looking for a little more certainty -- and defensiveness -- now that a few too many risky growth stocks are overbought as well as
Are You Really Ready to Start Collecting Social Security? 3 Signs It Might Be the Perfect Time
As you approach retirement, there are a few decisions you should consider to make sure you're as financially prepared as possible. This includes when you want to start taking withdrawals from your
$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges
Perceptive Advisors disclosed a sale of 1,002,282 Arcellx (NASDAQ:ACLX) shares in a February 17, 2026, SEC filing, with the estimated transaction value at $79.96 million based on quarterly average
Leveraged ETFs Are Among the Market's Most Aggressive Investment Tools. But Should You Avoid Them Altogether?
There are always investors who want to get rich as quickly as possible. That's why Wall Street has happily created exchange-traded funds (ETFs) that deliver double or even triple the market's
Arohi Asset Exits a Big Software Bet by Selling 1.7M DoubleVerify (DV) Shares Worth $20.6 Million
According to an SEC filing dated Feb. 18, 2026, Arohi Asset Management PTE Ltd. sold all 1,717,770 shares of DoubleVerify (NYSE: DV) during the fourth quarter. The estimated transaction value was
Could Buying XRP Today Set You Up for Life?
The formerly high-flying cryptocurrency XRP (CRYPTO: XRP) is down a head-spinning 60% over the past six months. That might not sound like the type of investment that could set you up for life.
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics (NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing.
According to a
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome (NASDAQ:IMNM), an estimated $12.20 million trade based on quarterly average pricing.
According to a February 17,
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio
Whether you plan on retiring a millionaire or already are one, your investing strategy is likely shifting over time. You spend your working years looking for upside in the name of growing your nest
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
Redmile Group disclosed a significant reduction in its Zymeworks (NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average
Vertiv Stock: Buy, Sell, or Hold?
Vertiv (NYSE: VRT) stock is a popular pick-and-shovel play on the increased build-out efforts related to artificial intelligence (AI) data centers. The company provides key cooling and power
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
Redmile Group reported a purchase of 16,317 shares of Krystal Biotech (NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based
Intuitive Surgical: This Robotic-Surgery Leader Could Keep Compounding for Another Decade
Intuitive Surgical (NASDAQ: ISRG) has faced challenges over the past year. President Donald Trump's aggressive tariffs are impacting its financial results, and it's now facing more competition than